region of the protein. Because of the sequence in which these recombinations occur, approximately one-third of normal mature T cells express a TCR containing a TCRB C1, while two-thirds express a TCRB containing a C2 constant region. In contrast, T cell leukemias and lymphomas show discrete rearrangements of the TCR loci reflecting their T cell clonal origin from a single cell. In many cases these clonal tumors also display surface expression of a TCR, which, as in the case of normal T cells, is restricted to contain either a TCRB C1 or a TCRB C2 chain.
Maciocia and co-workers exploited the TCRB-C1-or TCRB-C2-restricted pattern of TCR expression in T cells to develop a CAR T cell immunotherapy strategy directed against T cells that express TCRB C1. This provides a means to deliver T cell-specific antitumor effects while preventing the development of severe T cell immunodeficiency. To generate a TCRB-C1-specific CAR, the authors analyzed TCR monoclonal antibodies The T cell receptor (TCR) is a heterodimeric protein complex consisting of two chains named TCRA and TCRB, each encoded in a complex locus organized in modules that undergo an orchestrated recombination process during T cell development 3 . The TCR plays a central role in the function of the adaptive immune system by mediating the recognition of peptides presented by the major histocompatibility complex (MHC) at the surface of antigenpresenting cells, which triggers an immune response 4 . The modular structure and recombination of the TCRA and TCRB genes enables the generation of a polyclonal and diverse population of T cells, each armed with a different TCR, and an immune system capable of recognizing a broad number of antigen specificities. In the case of the TCRB gene, multiple V segments, each encoding a different variable region, can be recombined into two consecutive modules each consisting of a D diversity segment, a number of J joining segments and a C segment coding for the C-terminal constant Immunotherapy, a therapeutic modality that directs the immune system against tumor cells for the treatment of cancer, has been a frontline treatment for B cell lymphoma for almost two decades. Antibodies against CD20, a pan-B cell surface antigen, trigger effective antitumor responses in mature B cell tumors, and bispecific antibodies that bridge T cells and B cells can effectively direct cellular immune responses against malignant B cells 1 . In addition, cellular immunotherapy with T cells expressing chimeric antigen receptors (CAR)-engineered single-chain proteins capable of eliciting immune activation and designed to engage with a specific antigen of choice-has shown efficacy against an expanding number of B cell non-Hodgkin lymphomas 1 . However, pan-B cell-directed CAR T cells ablate both normal and tumor B cells, resulting in B cell immunosuppression. Although this can be managed clinically, a more targeted strategy with significant promise is the use of CAR T cells with specificity against the immunoglobulin κ light chain. Using this approach, both normal and malignant cells expressing κ light immunoglobulins are ablated by κ-light-chain-directed CAR T cells, yet normal λ-light-chain-expressing lymphocytes are spared, precluding the development of overt B cell immunodeficiency 2 .
In contrast to the progress in combating B cell malignancies, the development of immunotherapies targeting T cells has lagged behind, hampered by the technical constraints imposed by the potentially fatal immunosuppression resulting from the depletion of normal T lymphocytes targeted along with malignant T cell lymphoma cells. In this issue, Maciocia et al. exploit the monoallelic and clonal expression of the T cell receptor beta (TCRB) chain at the surface of malignant T cells to develop a targeted cellular immunotherapy for the treatment of T cell tumors.
Targeted cellular immunotherapy for T cell malignancies
Teresa Palomero 1,2 & Adolfo Ferrando [1] [2] [3] In a recent study, Maciocia et al. develop a novel T cell receptor beta (TCRB) constant C1-chain-directed cellular immunotherapy for the treatment of T cell malignancies. Despite these uncertainties, the prospect of a T cell-directed cellular immunotherapy is an exciting advance with the potential to transform the treatment of some of the most refractory forms of PTCL. The development of highaffinity CARs recognizing TCRB C2 would be a valuable next step for the authors' approach here, as this would enable the treatment of the remaining two-thirds of T cell tumors expressing TCRB-C2-containing TCRs.
that recognize only a fraction of mature T cells for their capacity to recognize selectively either TCRB C1 or TCRB C2 proteins. One of these antibodies, named JOVI-1, showed marked TCRB C1 specificity and was found to recognize a TCRB-C1-specific epitope that is a result of a two-amino-acid difference between TCRB C1 and TCRB C2. By introducing the variable chains of this antibody, which are responsible for TCRB C1 antigen recognition, in an artificial single-chain TCR, they engineered a CAR that binds selectively to TCRB-C1-containing TCRs. T cells expressing this CAR were able to effectively ablate normal and malignant T cells, but only if they expressed a TCRB-C1-containing TCR (Fig. 1) . Critically, though effective against monoclonal TCRB C1 tumor cells, the TCRB-C1-restricted activity of these CAR T cells spared normal lymphocytes expressing TCRB C2 TCRs and avoided the development of overt T cell immunodepletion in a humanized mouse model of disseminated T cell acute lymphoblastic leukemia.
The development of novel approaches for the treatment of relapsed and refractory T cell tumors is a priority in the therapy of nonHodgkin lymphomas. The high frequency of membrane TCR expression in angioimmunoblastic T cell lymphoma (AITL) and peripheral T cell lymphoma not otherwise specified (PTCL NOS), two tumor types characteristically associated with poor prognosis, makes these diseases particularly well suited for treatment with anti-TCRB-C1 CAR T cells. Moreover, TCR expression and signaling have been implicated as drivers of the growth and survival of PTCL lymphoma cells 5 , which could limit the capacity of clonal TCRB-C1-expressing tumor cells to escape from CAR T cell-mediated cell killing via downregulation of TCR expression. Yet open questions remain regarding potential side effects resulting from a reduced T cell repertoire composed only of TCRB C2 expressing T cells 6 . Also, preservation of the immune response could potentially limit the durability of the anti-TCRB-C1 CAR T cell
Fattening the role of Ca 2+ cycling in adaptive thermogenesis

Daniel Gamu & A Russell Tupling
A new study shows that deleting uncoupling protein 1 activates Ca 2+ cycling thermogenesis within beige fat, protecting mice against cold-induced hypothermia and dysglycemia following diet-induced obesity.
Daniel Gamu and A. Russell Tupling are in the Department of Kinesiology, University of Waterloo, Waterloo, Ontario, Canada. e-mail: rtupling@uwaterloo.ca Adaptive thermogenesis refers to the activation of mechanisms that generate heat for the purpose of regulating body temperature or metabolism in the face of environmental stresses, such as cold or change in diet. Brown adipose tissue (BAT) is specialized for adaptive thermogenesis owing to its expression of uncoupling protein 1 (UCP1). In response to norepinephrine, UCP1 generates heat by dissipating the mitochondrial proton gradient, at the expense of ATP synthesis (Fig. 1) . Although morphologically similar to BAT adipocytes, beige adipocytes are a distinct UCP1-expressing cell type arising from within subcutaneous white adipose tissue (WAT) 1 . In mice, expanding the beige adipocyte pool by activating expression of Prdm16, a major developmental regulator of beige fat cells, is protective against obesity by promoting energy expenditure 2 .
Recently, creatine cycling in beige fat has been described as a UCP1-independent mechanism of calorie wasting in mice 3 , suggesting that the role of UCP1 is not obligate for beige fat thermogenesis. In this issue, Ikeda et al. 4 show that beige fat utilizes another UCP1-independent thermogenic program consisting of futile Ca 2+ cycling (Fig. 1) . This study shows that beige adipocytes contain a repertoire of energy-wasting tools, and it appears that UCP1 is in fact dispensable for the thermogenic function of this tissue.
To examine UCP1-independent mechanisms of thermogenesis in beige fat, Ikeda et al. 4 first studied mice lacking UCP1 (Ucp1 −/− ) and transgenic mice that selectively expressed the thermogenic regulator Prdm16 in WAT, both in the presence (Prdm16-Tg) and absence (Prdm16-Tg × Ucp1 −/− ) of whole-body UCP1. They found that if Prdm16 was expressed the beige adipocyte pool was expanded, regardless of whether the mice expressed UCP1, and that Prdm16-Tg × Ucp1 −/− mice were able to maintain their core body temperature when exposed to cold owing to an enhanced ability of their subcutaneous WAT to produce heat. RNA sequencing revealed that cardiac Ca 2+ -handling genes were expressed in the WAT of these mice, including Serca2b and ryanodine receptor 2 (Ryr2), the cardiac Ca 2+ release channel. Serca2b expression was also induced in mouse and human beige adipocytes following treatment with a cAMP activator to mimic the effects of norepinephrine signaling, suggesting that the inducible response of Ca 2+ -handling genes is conserved across species, even in the presence of UCP1.
In idle skeletal muscle, leakage of Ca 2+ ions through sarco(endo)plasmic reticulum ryanodine receptors and their subsequent pumping back into the sarco(endo)plasmic reticulum by SERCAs comes at a significant energy cost 5 . The SERCA-inhibitory protein sarcolipin (SLN) uncouples SERCAs from ATP hydrolysis in
